What Do Oral Precursor Trials Show
In the SUSTAIN clinical trial program evaluating subcutaneous semaglutide for type 2 diabetes, once-weekly dosing (0.5 mg or 1.0 mg) reduced HbA1c by 1.5% to 1.8% from baseline, with superior glycemic control compared to specific comparators in head-to-head trials (SUSTAIN-7 vs dulaglutide
Cell 32 , 722738 (2021)
GLOW Peptide Dosage A standard 70 mg GLOW vial contains three peptides in fixed mass ratios: 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg full-length TB-4
MOTS-C Dosage Chart: Week-by-Week Titration Protocol No universally accepted clinical dosing standard for MOTS-c exists yet, and any protocol should be developed in consultation with a licensed physician familiar with peptide therapeutics
Antibodies specific for ACTL6A (Abcam, ab3882, 1:4000), GCLC (Abcam, ab190685, 1:4000), anti-NRF2 (Cell Signaling Technology, 12721 s, 1:2000), flag-tag (Sigma, F1804, 1:5000), and GAPDH (Proteintech, 10494-1-AP, 1:5000) were purchased from the indicated companies